BeiGene, Ltd. (ONC)vsVistra Corp. (VST)
ONC
BeiGene, Ltd.
$317.00
+1.17%
HEALTHCARE · Cap: $33.06B
VST
Vistra Corp.
$147.72
-4.05%
UTILITIES · Cap: $52.12B
Smart Verdict
WallStSmart Research — data-driven comparison
Vistra Corp. generates 232% more annual revenue ($17.74B vs $5.34B). ONC leads profitability with a 5.4% profit margin vs 5.3%. VST trades at a lower P/E of 70.6x. VST earns a higher WallStSmart Score of 53/100 (C-).
ONC
Hold42
out of 100
Grade: D
VST
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+79.5%
Fair Value
$1717.18
Current Price
$317.00
$1400.18 discount
Margin of Safety
-53.3%
Fair Value
$101.06
Current Price
$147.72
$46.66 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Large-cap with strong market position
Areas to Watch
Trading at 8.1x book value
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Trading at 19.1x book value
5.3% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : VST
The strongest argument for VST centers on Market Cap. Revenue growth of 13.6% demonstrates continued momentum. PEG of 1.38 suggests the stock is reasonably priced for its growth.
Bear Case : ONC
The primary concerns for ONC are Price/Book, EPS Growth, Return on Equity. A P/E of 120.4x leaves little room for execution misses.
Bear Case : VST
The primary concerns for VST are Price/Book, Profit Margin, Piotroski F-Score. A P/E of 70.6x leaves little room for execution misses. Debt-to-equity of 3.36 is elevated, increasing financial risk.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while VST is a value play — different risk/reward profiles.
VST carries more volatility with a beta of 1.45 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (161M), providing more financial flexibility.
Bottom Line
VST scores higher overall (53/100 vs 42/100) and 13.6% revenue growth. ONC offers better value entry with a 79.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Vistra Corp.
UTILITIES · UTILITIES - INDEPENDENT POWER PRODUCERS · USA
Vistra Corp. The company is headquartered in Irving, Texas.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?